Peptides for acne remain experimental: no peptide is FDA-approved for acne, the most advanced antimicrobial peptide gel, omiganan, never reached approval after acne and rosacea trials, and cosmetic peptide products have only small studies.[4][5][6] The American Academy of Dermatology’s 2024 guideline strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics and oral doxycycline, with isotretinoin for severe acne, so start there.[1]
This guide covers proven care first, then what antimicrobial and cosmetic peptide research shows. For background, see our peptide basics hub.
Evidence-graded table
| Peptide or treatment | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Benzoyl peroxide, topical retinoids, topical antibiotics, doxycycline | FDA-approved for this use | Strong recommendations in AAD guideline[1] | Approved or OTC monograph | None |
| Oral isotretinoin | FDA-approved for this use | Strongly recommended for severe, scarring or resistant acne[1] | Approved (Rx) | None |
| Azelaic acid 20% | FDA-approved for this use | Conditional recommendation[1] | Approved for mild to moderate inflammatory acne[2] | None |
| Omiganan (antimicrobial peptide gel) | Human RCTs (acne results not posted; rosacea mixed) | Phase 2 acne trial completed, no results; one of two phase 3 rosacea trials missed its goals[4][5][6] | Not approved | None |
| Granulysin-derived peptides (GDP-20) | Small human studies | Added to low-dose isotretinoin in 60 patients; no placebo[8] | Not approved in US | None |
| Cleanser with 5-ALA and peptides | Small human studies (one RCT) | Fewer lesions than a basic cleanser in 60 people over 8 weeks[9] | Cosmetic | None |
| LL-37, KPV | Animal or lab only (for acne) | No acne treatment trials | Not approved | LL-37, KPV |
| GHK-Cu | No evidence, marketing only (for acne) | No acne trials | Cosmetic ingredient | GHK-Cu |
Results come from different groups of people and are not head-to-head comparisons.
Start with what works
The AAD guideline, built from a systematic review, makes 18 recommendations.[1]
- Strong recommendations: benzoyl peroxide, topical retinoids, topical antibiotics and oral doxycycline
- Isotretinoin: strongly recommended for severe acne, acne causing scarring or distress, or acne that fails other treatment
- Conditional recommendations: topical clascoterone, salicylic acid and azelaic acid, plus oral minocycline, sarecycline, combined birth control pills and spironolactone
- Good practice: combine topicals that work in different ways and limit oral antibiotic use
Azelaic acid 20% cream is FDA-approved for mild to moderate inflammatory acne.[2] A dermatologist can match treatment to your acne type, skin tone and scarring risk.
Why researchers are interested in antimicrobial peptides
Antimicrobial peptides (AMPs) are short proteins made by the skin’s immune system, such as cathelicidin LL-37, beta-defensins and dermcidin. They kill bacteria and help coordinate inflammation. A 2024 review notes that AMP levels are elevated in acne and proposes they are a compensatory response to a weakened skin barrier. It describes AMPs as potential candidates for acne treatment, not established ones.[3]
The appeal is clear: rising resistance to the antibiotics used for acne. Our antimicrobial peptides research guide covers this wider field, and LL-37 vs defensins vs magainin compares the main natural AMPs.
Omiganan: the acne and rosacea trials
Omiganan is a synthetic AMP developed as a topical gel (CLS001). Its ClinicalTrials.gov records show:
- Acne: a phase 2, vehicle-controlled trial in 320 women with moderate to severe acne was completed in August 2016. No results have been posted.[4]
- Rosacea, first phase 3: in 263 people with papulopustular rosacea, inflammatory lesions fell by 19.8 on omiganan and 20.9 on the plain gel after 12 weeks, with no significant difference. About a quarter of each group improved by two grades.[5]
- Rosacea, second phase 3: in 463 people, omiganan reduced lesions by 18.1 versus 13.5 on the plain gel, and 26.3% versus 16.9% improved by two grades, both statistically significant.[6]
With one negative and one modestly positive phase 3 trial, omiganan has not been approved. In atopic dermatitis, it reduced Staphylococcus bacteria on the skin but did not improve symptoms in an 80-patient phase 2 trial.[7] Killing bacteria on the skin does not reliably translate into clearer skin.
Cosmetic and other peptide products
- Granulysin-derived peptides: in a Russian study of 60 patients, topical GDP-20 plus low-dose isotretinoin reduced lesions, compared with isotretinoin alone. There was no placebo cream, and both groups received an effective acne drug.[8]
- Peptide cleanser: in a double-blind trial of 60 people with mild to moderate acne, a cleanser with 5-aminolevulinic acid and peptides reduced inflammatory and non-inflammatory lesions more than a basic cleanser over 8 weeks.[9] The specific peptides’ contribution is unclear.
- LL-37 and KPV: these are promoted online, but neither has published acne treatment trials. FDA’s compounding safety-risk page now lists both among substances withdrawn by their nominators; its notes cite possible immune reactions for LL-37 and no human exposure data at all for KPV.[10]
Because cosmetics cannot claim to treat disease, peptide skincare products describe “clearer-looking” or “balanced” skin instead.[11] See our cosmetic peptides evidence review.
If you want to add a peptide product
Peptide skincare is unlikely to harm acne-prone skin, but it should not crowd out treatments that work.
- Keep your core routine. Benzoyl peroxide, a retinoid or your prescription comes first.[1]
- Choose light, non-comedogenic textures such as serums or gels rather than rich creams or oils.
- Add one product at a time and wait 4 to 6 weeks before judging it, since acne naturally flares and settles.
- Watch for irritation. Retinoids and benzoyl peroxide already dry the skin; layering many actives can make redness worse.
- Skip injections and “research” vials. Products sold for lab use are not made for skin.
It is also worth knowing why researchers keep pursuing peptides here. The AAD guideline advises limiting oral antibiotic use and pairing antibiotics with topical treatments, partly to reduce resistance.[1] An antimicrobial peptide that clears skin without fueling resistance would fill a real gap, which is why the field continues despite omiganan’s setbacks.[3]
Questions to discuss with a dermatologist
- Which first-line combination fits my acne type and skin?
- Would isotretinoin or a hormonal option make sense if topicals fail?
- Is a peptide product I’m considering likely to irritate my skin or clash with my treatment?
The bottom line
Peptides may one day offer an alternative to antibiotics for acne, but that day has not arrived. Use proven treatments first; if you add a peptide product, treat it as optional skincare, not therapy.
